Analysts’ Opinions Are Mixed on These Healthcare Stocks: Becton Dickinson (BDX) and Moderna (MRNA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Becton Dickinson (BDX – Research Report) and Moderna (MRNA – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Becton Dickinson (BDX)
Bank of America Securities analyst Travis Steed reiterated a Hold rating on Becton Dickinson today and set a price target of $207.00. The company’s shares closed last Thursday at $208.35.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Currently, the analyst consensus on Becton Dickinson is a Moderate Buy with an average price target of $205.00, implying a -0.7% downside from current levels. In a report issued on January 7, RBC Capital also maintained a Hold rating on the stock with a $210.00 price target.
See the top stocks recommended by analysts >>
Moderna (MRNA)
In a report released today, Alec Stranahan from Bank of America Securities reiterated a Sell rating on Moderna, with a price target of $24.00. The company’s shares closed last Thursday at $39.36, close to its 52-week low of $29.25.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
Currently, the analyst consensus on Moderna is a Hold with an average price target of $29.07.
